Successful treatment of classic pyoderma gangrenosum with intralesional infliximab injection: A case report

Kourosh Ahmadi; Elham Aflaki; Mojgan Akbarzade Jahromi; Ladan Dastgheib

doi:10.1111/ajd.14072

Successful treatment of classic pyoderma gangrenosum with intralesional infliximab injection: A case report

Australas J Dermatol. 2023 Aug;64(3):e252-e255. doi: 10.1111/ajd.14072. Epub 2023 May 16.

Authors

Kourosh Ahmadi^{1

2}, Elham Aflaki³, Mojgan Akbarzade Jahromi⁴, Ladan Dastgheib^{1

2}

Affiliations

¹ Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
² Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
³ Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
⁴ Pathology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

PMID: 37192138
DOI: 10.1111/ajd.14072

Abstract

Pyoderma gangrenosum (PG) is a rare dermatological disease characterized by the rapid development of painful skin ulcers. While systemic infliximab is considered a standard treatment for patients with PG, herein, we report our success with the use of intralesional infliximab in a 40-year-old woman with systemic lupus erythematosus (SLE) and PG.

Keywords: Remicade; drug therapy; intralesional injection; pyoderma gangrenosum; tumour necrosis factor-α inhibitors.

Publication types

Case Reports

MeSH terms

Adult
Female
Humans
Infliximab / therapeutic use
Lupus Erythematosus, Systemic* / complications
Pyoderma Gangrenosum* / drug therapy
Pyoderma Gangrenosum* / etiology

Substances

Infliximab